- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04947137
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a prospective, open-label, multicenter, single-dose study designed to develop a normative database of TUVjoint in HCs and to assess the feasibility of qualitative and quantitative SPECT/CT assessments in HCs and subjects with active RA.
This study is stratified into 2 arms. Arm 1 is comprised of HCs and Arm 2 is comprised of HCs and clinically diagnosed RA subjects on stable treatment.
Studietype
Inschrijving (Verwacht)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Florida
-
Miami Lakes, Florida, Verenigde Staten, 33014
- San Marcus Research Clinic
-
Palmetto Bay, Florida, Verenigde Staten, 33157
- Innovation Medical Research Center
-
-
Ohio
-
Kettering, Ohio, Verenigde Staten, 45429
- Kettering Medical Center
-
-
Oklahoma
-
Tulsa, Oklahoma, Verenigde Staten, 74137
- Essential Medical Research
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Verenigde Staten, 16635
- Altoona Center For Clinical Research
-
-
Texas
-
San Antonio, Texas, Verenigde Staten, 78215
- Sun Research Institute
-
Webster, Texas, Verenigde Staten, 77598
- Tranquility Research
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
ALL SUBJECTS
- The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) authorization before the initiation of any study-related procedures.
The subject has agreed to not engage in any diet, lifestyle, or medication changes until study completion.
HEALTHY CONTROL SUBJECTS
- The subject is 30 years of age or greater at the time of consent.
- The subject is deemed to be clinically free of any inflammatory disease(s), autoimmune disease(s), or arthropathies and has not experienced joint pain for at least 28 days prior to the consent date.
- The subject is not currently on anti-inflammatory drugs (including non-steroidal anti-inflammatory drugs [NSAIDs]) and has not taken any anti-inflammatories for at least 28 days prior to the consent date.
- For all ongoing concomitant medications, the subject has maintained a stable dose for at least 28 days prior to the consent date.
CLINICALLY DIAGNOSED ACTIVE RA SUBJECTS
3. The subject is at least 18 years of age and was ≥ 18 years of age at the time of RA diagnosis.
4. The subject has moderate to severe RA as determined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria (score of ≥ 6/10).
5. The subject has a 28-joint disease activity score (DAS28) of ≥ 3.2 (includes the Erythrocyte Sedimentation Rate [ESR] test and Visual Analog Scale [VAS]).
6. Subjects receiving traditional DMARDs must have been on therapy for ≥ 90 days and at a stable dose for ≥ 30 days prior to the imaging visit (Day 0). 7. If the subject is receiving bDMARD or janus kinase (JAK) inhibitor therapy, they have been at a stable dose > 60 days prior to the imaging visit (Day 0). 8. If the subject is receiving NSAIDs or oral corticosteroids, the dose has been stable for ≥ 28 days prior to the imaging visit (Day 0). The corticosteroid dose must be ≤ 10 mg/day of prednisone or an equivalent steroid dose.
Exclusion Criteria:
- The subject is pregnant or lactating.
- The subject size or weight is not compatible with imaging per the investigator.
- The subject is currently receiving radiation therapy or chemotherapy or has received radiation therapy or chemotherapy in the past six months.
- The subject has had a finger, hand, and/or wrist amputation or hand or wrist joint arthroplasty.
- The subject has renal insufficiency as demonstrated by a glomerular filtration rate of < 60 mL/min.
- The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase [SGPT]) or AST (aspartate aminotransferase [SGOT]) greater than 2 times the upper limit of normal.
- The subject has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation or compromise the safety of the subject or the quality of the data.
- The subject has any unstable medical illnesses, including hepatic, renal, gastroenterologic, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
- The subject has a known allergy to or has had an adverse reaction to dextran exposure.
- The subject has received an investigational product within 30 days prior to Tc 99m tilmanocept administration (Day 0).
- The subject has received intra-articular corticosteroid injections ≤ 8 weeks prior to Tc 99m tilmanocept administration (Day 0).
- The subject has received any radiopharmaceutical within 7 days or 10 half-lives prior to Tc 99m tilmanocept administration (Day 0).
- Healthy Controls only: The subject has a positive rheumatoid factor and an elevated ESR or CRP.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Subjects Free of Inflammatory Disease
The first arm will be comprised of HCs who are deemed to be clinically free of inflammatory diseases, arthropathies, and/or arthroplasties and clinically free of joint pain for at least 28 days prior to the consent date.
|
Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Andere namen:
|
Experimenteel: Healthy Controls and RA Subjects on Stable Therapy
The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment.
|
Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Normal Limits of TUVjoint in Healthy Subjects
Tijdsspanne: Up to 39 days
|
The normal limits of TUVjoint (on a per joint basis) in HC subjects, which are defined as the 5 and 95 percentiles of TUVjoint of bilateral joints (i.e., bilateral wrists, metacarpophalangeal joint [MCPs], proximal interphalangeal [PIPs]).
|
Up to 39 days
|
Qualitative Evaluation of SPECT/CT for Tilmanocept Localization
Tijdsspanne: Up to 39 days
|
Presence/absence of tilmanocept localization in the hands and wrists will be summarized with frequency counts and percentages by reader and joint.
|
Up to 39 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Normal Distribution of TUVjoint
Tijdsspanne: Up to 39 days
|
Applicability of the Normal (Gaussian) distribution to TUVjoint data as assessed by normal quantile plots provided per joint and reader and p-value for the Shapiro-Wilk test of Normality.
|
Up to 39 days
|
Quantitative Evaluation of SPECT/CT
Tijdsspanne: Up to 39 days
|
Determination of joint-specific standardized uptake value (SUV) from SPECT/CT imaging within synovial spaces of the bilateral hands and wrists in HCs and RA subjects.
|
Up to 39 days
|
Planar and SPECT/CT Comparison
Tijdsspanne: Up to 39 days
|
Assessment of the predictive value of planar scans for SPECT/CT scans.
|
Up to 39 days
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Michael Blue, MD, Navidea Biopharmaceuticals
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NAV3-35
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Reumatoïde artritis
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Zhejiang Chinese Medical University; Zhejiang...Werving
-
Texas Tech University Health Sciences Center, El...Beëindigd
-
Nantes University HospitalVoltooidSeptische arthritisFrankrijk
-
wangxiaodongVoltooid
-
Second Affiliated Hospital, School of Medicine,...VoltooidSeptische arthritisChina
-
Rennes University HospitalVoltooid
-
Assiut UniversityNog niet aan het wervenSeptische arthritis
-
Assiut UniversityNog niet aan het werven
-
Assistance Publique - Hôpitaux de ParisWerving
-
Khoo Teck Puat HospitalOnbekend
Klinische onderzoeken op Tc99m tilmanocept
-
Cardinal Health 414, LLCBeëindigdBaarmoeder Cervicale NeoplasmataVerenigde Staten
-
Navidea BiopharmaceuticalsActief, niet wervendReumatoïde artritisVerenigde Staten
-
Navidea BiopharmaceuticalsNational Cancer Institute (NCI); National Institutes of Health (NIH)VoltooidHIV-infecties | Kaposi-sarcoomVerenigde Staten
-
Cardinal Health 414, LLCVoltooidMelanoma | RhabdomyosarcoomVerenigde Staten
-
Navidea BiopharmaceuticalsVoltooidNiet-alcoholische steatohepatitis | NASH - Niet-alcoholische steatohepatitisVerenigde Staten
-
UMC UtrechtWerving
-
Navidea BiopharmaceuticalsVoltooidReumatoïde artritisVerenigde Staten
-
Navidea BiopharmaceuticalsIngetrokken
-
University Hospital, GhentNorgineIngetrokkenBorstkanker | Schildwacht lymfeklierBelgië
-
Washington University School of MedicineLloyd J. Old STAR ProgramBeëindigdNeoplasmata van het centrale zenuwstelsel | Tumor van het centrale zenuwstelselVerenigde Staten